3752-24-7

Basic information

• Product Name: 4,5,6,7-tetrahydro-1H-benzoimidazole
• Synonyms: 4,5,6,7-TETRAHYDRO-1H-BENZIMIDAZOLE
• CAS NO: 3752-24-7
• Molecular Formula: C₇H₁₀N₂
• Molecular Weight: 122.17
• Product Categories: Imidazol&Benzimidazole
• Mol File: 3752-24-7.mol

Chemical Properties

• Melting Point: 150 °C
• Boiling Point: 335 °C at 760 mmHg
• Flash Point: 183.6 °C
• Appearance: /
• Density: 1.133 g/cm³
• Vapor Pressure: 0.00024mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: 2-8°C
• PKA: 15.15±0.20(Predicted)
• CAS DataBase Reference: 4,5,6,7-tetrahydro-1H-benzoimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5,6,7-tetrahydro-1H-benzoimidazole(3752-24-7)
• EPA Substance Registry System: 4,5,6,7-tetrahydro-1H-benzoimidazole(3752-24-7)

Safety Data

• Hazardous Substances Data: 3752-24-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,5,6,7-Tetrahydro-1H-benzoimidazole is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a versatile building block for the development of new drugs with potential therapeutic applications.
Used in Chemical Synthesis:
4,5,6,7-Tetrahydro-1H-benzoimidazole is used as a reactant in the preparation of imidazolylnitroquinoxalinedione, a compound with potential applications in various fields, including materials science and pharmaceuticals. Its reactivity and structural features make it a valuable component in the synthesis of complex organic molecules.
Used in Research and Development:
Due to its unique chemical properties, 4,5,6,7-tetrahydro-1H-benzoimidazole is also utilized in research and development for the exploration of new chemical reactions and the discovery of novel compounds with potential applications in various industries.

Synthesis Reference(s)

The Journal of Organic Chemistry, 41, p. 19, 1976 DOI: 10.1021/jo00863a004

InChI:InChI=1/C7H10N2/c1-2-4-7-6(3-1)8-5-9-7/h5H,1-4H2,(H,8,9)

Upstream product

• 51-17-2 benzoimidazole 
• 77287-34-4 formamide 
• 822-87-7 2-Chlorocyclohexanone 
• 50-00-0 formaldehyd 
• 533-60-8 cyclohexanone-2-ol 
• 463-52-5 formamidine 
• 7664-93-9 sulfuric acid 
• 6313-33-3 formamidine hydrochloride 
• 3473-63-0 formamidine acetic acid 

Downstream Products

• 116764-34-2 4-(4,5,6,7-tetrahydro-1H-benzimidazol-1-yl)-β-methyl-γ-oxobenzenebutanoic acid 
• 90514-71-9 4-(4,5,6,7-tetrahydro-1H-benzimidazol-1-yl)benzaldehyde 
• 26751-12-2 1-benzyl-4,5,6,7-tetrahydro-1H-benzo[d]imidazole 
• 675123-11-2 1-(methoxymethyl)-4,5,6,7-tetrahydro-1H-benzimidazole 
• 675123-13-4 1-(benzyl)-4,5,6,7-tetrahydro-1H-benzimidazole-2-carboxylic acid methyl ester 
• 90514-78-6 1-[4-(4,5,6,7-tetrahydro-1H-benzimidazol-1-yl)phenyl]-2-propanone 
• 90514-80-0 1-[4-((E)-2-Nitro-propenyl)-phenyl]-4,5,6,7-tetrahydro-1H-benzoimidazole 
• 90514-83-3 1,2-dihydro-6-methyl-2-oxo-5-[4-(4,5,6,7-tetrahydro-1H-benzimidazol-1-yl)phenyl]-3-pyridine carbonitrile 
• 97150-57-7 4,5-dihydro-6-[4-(4,5,6,7-tetrahydro-1H-benzimidazol-1-yl)phenyl]-5-methyl-3(2H)-pyridazinone 
• 720000-06-6 4-(4,5,6,7-tetrahydro-benzoimidazol-1-yl)-3-trifluoromethyl-benzonitrile 
• 900183-30-4 4,5,6,7-tetrahydro-1H-benzimidazole-2-yl[4-(trifluoromethyl)phenyl]methanone 
• 910654-38-5 C₁₄H₁₂F₃N₃O₂ 
• 840503-10-8 (1-allyl-4,5,6,7-tetrahydro-1H-benzimidazole-2-yl)[4-methylphenyl]methanone 

Relevant articles and documents

Rational Design, Synthesis and Evaluation of Novel C6-Bicycloalkaneimidazole Containing Imidazo[1,2-b]pyridazines for ASK1 Inhibition

Apoptosis signal-regulating kinase 1 (ASK1) is a member of mitogen-activated protein kinase kinase kinase (MAP3K) family that involves downstream phosphorylation of MAP kinases, c-Jun N-terminal kinases, and p38 MAP kinases. ASK1 inhibitors could possibly be beneficial for ameliorating the development and progression of diseases. Especially, ASK1 has been of interest as one of therapeutic targets for nonalcoholic fatty liver disease as the most common chronic liver diseases including simple steatosis and nonalcoholic steatohepatitis. In this manuscript, novel ASK1 inhibitor lead KTA-29 which has an imidazo[1,2-b]pyridazine core with novel C6-bicycloheptaneimidazole is disclosed. With the novel imidazo[1,2-b]pyridazine core, structure-activity-relationship study for ASK1 potency is described and KTA-29 affinity toward ASK1 with molecular modeling study is explained.

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

TETRAHYDROBENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted 4,5,6,7-tetrahydrobenzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders;

NOVEL HETEROARYL DERIVATIVE

A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. wherein the ring Z is an optionally substituted heteroaryl, W4 is a single bond, lower alkylene, etc., Ar2 is an optionally substituted aryl, etc., W3 is a single bond, lower alkylene, etc., Ar1 is an optionally substituted arylene, etc., each of W1 and W2 is an optionally substituted lower alkylene, etc., and R1 is carboxyl, an alkoxycarbonyl.

NOVEL HETEROARYL DERIVATIVE

A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. (1) wherein: the ring Z is an optionally substituted heteroaryl, W4 is a single bond, lower alkylene, etc., Ar2 is an optionally substituted aryl, etc., W3 is a single bond, lower alkylene, etc., Ar1 is an optionally substituted arylene, etc., each of W1 and W2 is an optionally substituted lower alkylene, etc., and R1 is carboxyl, an alkoxycarbonyl, etc.

Biaryl derived amide modulators of vanilloid VR1 receptor

The invention is directed to novel vanilloid receptor type 1 (VR1) ligands. More specifically, the invention relates to novel biaryl-derived amides that are potent antagonists or agonists of VR1. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

Oxidative rearrangement of imidazoles with dimethyldioxirane

Tetrahydrobenzimidazoles, on treatment with dimethyldioxirane, rearrange to provide 5-imidazolones exclusively. These rearrangements proceed with a broad range of substrates and with good to excellent levels of diastereoselectivity.